期刊文献+

含甲基咪唑的抗肿瘤转移NAMI-A衍生物的水解和电化学性质 被引量:7

Hydrolytic and Electrochemical Property of Antimetastasis NAMI-A Derivatives Containing Methylimidazole
下载PDF
导出
摘要 合成了trans-[RuCl4(DMSO)(4-MeIm)][(4-MeIm)H].HCl(4-MeIm=4-甲基咪唑)(1)和trans-[RuCl4(DMSO)(N-MeIm)][(N-MeIm)H](N-MeIm=N-甲基咪唑)(2).通过紫外-可见光谱、核磁共振谱和循环伏安法研究了配体结构(4-甲基咪唑,N-甲基咪唑)对NAMI-A衍生物的水解机理、水解动力学、电化学性质及溶液稳定性的影响.结果表明,化合物1的Ⅰ氯、Ⅱ氯及DMSO水解反应机理与NAMI-A相似,但其各级水解速率皆比NAMI-A快,即将推电子的甲基引入咪唑环(4位)明显加快了NAMI-A衍生物的Ⅰ氯、Ⅱ氯及DMSO水解反应速率.化合物在酸性溶液中的稳定性高于中性溶液. trans-[RuCl4(DMSO)(4-MeIm)][(4-MeIm)H]·HCl(4-MeIm=4-Methylimidazole,1) and trans-[RuCl4(DMSO)(N-MeIm)][(N-MeIm)H](N-MeIm=N-Methylimidazole,2) were synthesized.The influence of ligand structure(4-MeIm and N-MeIm) on hydrolytic mechanism-kinetics,electrochemical properties and solution stabilities of Ru-NAMI-A derivatives was studied by UV,NMR and cyclic voltammetry.The result shows that the 1st and 2nd chloro-hydrolysis as well as DMSO-hydrolysis mechanisms for two compounds are very similar to that for NAMI-A.However,the hydrolytic rates of compound 1 are obviously faster than that of compound 2,which means that introducing electron donating group(methyl) into imidazole ring(C4) of NAMI-A would accelerate hydrolytic reaction of Ru-NAMI-A derivatives.The stability of the complexes in acetic buffer solution is much more stable than that of in neural solution.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2011年第2期210-217,共8页 Chemical Journal of Chinese Universities
基金 澳门科技发展基金(批准号:012/2009/A1) 国家科技部国际合作基金(批准号:2005DFA30990) 中国中医科学院基本科研业务费自主选题项目(批准号:ZZ2006120,Z02089)资助
关键词 钌配合物 抗肿瘤转移 水解动力学 稳定性 Ruthenium complex Antimetastasis Hydrolytic kinetics Stability
  • 相关文献

参考文献26

  • 1Sava G. , Clerici K. , Capozzi I. , Cocchietto M. , Gagliardi R. , Alessio E. , Mestroni G. , Perbellini A.. Anticancer Drugs[J], 1999, 10(1) : 129-138.
  • 2Bergamo A. , Gava B. , Alessio E. , Mestroni G. , Sedi B. , Cocchietto M. , Zorzet S. , Sava G.. Int. J. Oncol. [ J] , 2002, 21(6) : 1331-1338.
  • 3Sara G. , Gagliardi R. , Bergamo A. , Alessio E. , Mestroni G.. Anticancer Res. [J] , 1999. 19(2A) : 969-972.
  • 4Sara G. , Bergamo A. , Zorzet S. , Gava B. , Casarsa C. , Cocchietto M. , Furlani A. , Scarcia V. , Serli B. , Iengo E. , Alessio E. ,Mestroni G.. Eur. J. Cancer[J] , 2002, 38(3) : 427-435.
  • 5Sava G. , Gagliardi R. , Cocchietto M. , Clerici K. , Capozzi I. , Marrella M. , Alessio E. , Mestroni G. , Milanino R.. Pathol. Oncol. Res. [J], 1998, 4(1): 30-36.
  • 6Casini A. , Mastrobuoni G. , Terenghi M. , Gabbiani C. , Monzani E. , Moneti G. , Casella L. , Messori L. J.. Biol. Inorg. Chem. [J], 2007, 12(8): 1107-1117.
  • 7Pluim D. , van Waardenburg R. C. , Beijnen J. H. , Schellens J. H.. Cancer Chemother. Pharmacol. [J], 2004, 54(1) : 71--78.
  • 8Bacac M., Hotze A. C., van der Schilden K., Haasnoot J. G., Pacor S., Alessio E., Sava G., Reedijk J.. J. Inorg. Biochem. [J], 2004, 98(2) : 402-412.
  • 9Rademaker-Lakhai J. M. , van den Bongard D. , Pluim D. , Beijnen J. H. , Schellens J. H.. Clin. Cancer Res. [J], 2004, 10(11) : 3717 --3727.
  • 10王晓勇,郭子建.金属抗癌药物设计的新策略和新趋势[J].化学进展,2009,21(5):845-855. 被引量:17

二级参考文献109

  • 1Dyson P J, Sava G. J. Chem. Soc., Dalton Trans., 2006:1929 -1933
  • 2Bouma M, Nuijen B, Jansen M T, et al. Int. J. Pharrn., 2002, 248(1-2):239-246
  • 3Bergamo A, Gava B, Alessio E, et al. Int. J. Oncol., 2002,21 (6):1331-1338
  • 4Brindell M, Piotrowska D, Shoukry A A, et al. J. Biol. Inorg. Chem., 2007,12(6):809-818
  • 5Mestroni G, Allessio E, Sava G. United States Patent. Patent No.US 6,221,905 B1, 2001.
  • 6Mestroni G, Allesio E, Sava G, et al. United States Patent,Patent No.US 6,921,824 B1, 2005.
  • 7Bergamo A, Stocco G, Casarsa C, et al. Int. J. Oncol., 2004, 24:373-379
  • 8Bacac M, Hotze A C, van der Schilden K, et al. J. lnorg. Biochem., 2004,98(2):402-412
  • 9Messori L, Orioli P, Vullo D, et al. Eur. J. Biochem., 2000, 267(4): 1206- 1213
  • 10Frausin F, Scarcia V, Cocchietto M, et al. J. Pharmacol. Exp. Ther., 2005,313(1):227-233

共引文献19

同被引文献87

  • 1王国民,陈伟.泌尿系统肿瘤治疗的进展与展望[J].肿瘤防治研究,2014,41(2):97-101. 被引量:25
  • 2蒲小华,陈绘丽,韩高义,杨频.带有位阻基团的钌多吡啶配合物与DNA键合及其光断裂DNA性质的研究[J].化学学报,2007,65(15):1464-1468. 被引量:1
  • 3贾学恩.几种肿瘤细胞和蛋白质纳米生物传感的压电电化学研究.湖南师范大学,2009.
  • 4薛亚东.肿瘤细胞表面聚糖的电化学检测与细胞成像分析.南京大学,2010.
  • 5干宁,葛从辛,王志颖,余杨峰,陆敏娟.新型8-氨基喹啉-蛋氨酸衍生物合钌金属药物的合成和细胞毒活性及其与DNA相互作用研究[J].中国药学杂志,2007,42(19):1508-1512. 被引量:2
  • 6Liu J,Zheng W J,Shi S,et al.Synthesis,antitumor activity and structure-activity relationships of s series of Ru(Ⅱ)complexes[J].J.Inorg.Biochem,2008,102:193-202.
  • 7Casini A,Mastrobuoni G,Terenghi M,et al.Ruthenium anticancer drugs and proteins:a study of the interactions of theruthenium(Ⅲ)complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(Ⅲ)]with hen egg whitelysozyme and horse heart cytochrome[J].Biol.Inorg.Chem,2007,12(8):1107-1117.
  • 8Bell T W,Anugu S,Bailey P,et al.Synthesis and structure-activity relationship studies of CD4down-modulatingcyclotriazadisulfonamide(CADA)analogues[J].J.Med.Chem,2006,49:1291.
  • 9Ioannis B,Alberta B,Gianni S,et al.Influence of the anionic ligands on the anticancer activity of Ru(Ⅱ)-dmsocomplexes:Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chlorideprecursors[J].J.Inorg.Biochem,2008,102:606-617.
  • 10Clarke M J,Zhu F,Frasca D R.Non-platinum chemotherapeutic metallopharmaceuticals[J].Chem Rev,1999,99(9):2511-2533.

引证文献7

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部